ARS Pharmaceuticals Says CHMP Of European Medicines Agency Adopted Positive Opinion On Application For Marketing Authorization For EURneffy (Adrenaline Nasal Spray)

6/28/24 6:31:51 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SPRY alert in real time by email

The CHMP recommended related market authorization in the European Union (EU) for the emergency treatment of allergic reactions (anaphylaxis). The CHMP positive opinion will now be submitted to the European Commission (EC) for the formal marketing authorization process, which is expected to occur in Q3 2024.

Get the next $SPRY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SPRY

Date	Price Target	Rating	Analyst
8/20/2024		Overweight	Cantor Fitzgerald
8/13/2024	$18.00 → $22.00	Outperform → Strong Buy	Raymond James
8/12/2024	$19.00 → $20.00	Outperform	Leerink Partners
7/25/2024	$18.00	Outperform	Raymond James
3/5/2024	$6.00 → $18.00	Market Perform → Outperform	Leerink Partners
2/20/2024		Mkt Perform → Outperform	William Blair
9/20/2023		Outperform → Mkt Perform	William Blair
1/31/2023	$10.00	Outperform	Wedbush

More analyst ratings

$SPRY
Press Releases

Fastest customizable press release news feed in the world

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Agreement leverages ALK's global footprint in developing and commercializing innovative allergy products ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of up to $465 million plus double-digit royalties on net sales ARS Pharma retains all U.S. rights, and existing partnerships in Japan, China, Australia and New Zealand with Alfresa, Pediatrix and CSL, respectively SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced a licens
11/11/24 7:00:00 AM ET
$ALK
$SPRY
Air Freight/Delivery Services
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (("ARS Pharma", NASDAQ:SPRY). The agreement grants ALK exclusive global rights to the neffy® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key elements in ALK's new strategy Allergy+ and supports ALK's long-term financial ambitions. Needle-free, nasal delivery of adrenaline has the potential to become an important treatment option in anaphylaxisALK also gains rights to future indications, including acute urticaria flares (in development)ALK to pay USD 145 million in up
11/9/24 5:29:53 PM ET
$SPRY
Biotechnology: Pharmaceutical Preparations
Health Care
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that seven abstracts will be featured tomorrow, Friday, October 25 at the 2024 ACAAI Annual Scientific Meeting taking place in Boston, Massachusetts. The posters highlight a wide range of studies focused on intranasal epinephrine administration, including cardiovascular safety, human factor study of carrying two devices at all times, and real-world administration data in pediatric patients. "The research being p
10/24/24 8:30:00 AM ET
$SPRY
Biotechnology: Pharmaceutical Preparations
Health Care

ARS Pharmaceuticals Says CHMP Of European Medicines Agency Adopted Positive Opinion On Application For Marketing Authorization For EURneffy (Adrenaline Nasal Spray)

Chat with this insight

Recent Analyst Ratings for
$SPRY

$SPRY
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Ra Capital Management, L.P. bought $13,289,410 worth of shares (1,401,299 units at $9.48) (SEC Form 4)

$SPRY
SEC Filings

SEC Form 10-Q filed by ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 8-K filed by ARS Pharmaceuticals Inc.

$SPRY
Press Releases

Fastest customizable press release news feed in the world

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

$SPRY
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on ARS Pharmaceuticals

ARS Pharmaceuticals upgraded by Raymond James with a new price target

Leerink Partners reiterated coverage on ARS Pharmaceuticals with a new price target

$SPRY
Financials

Live finance-specific insights

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

$SPRY
Market Insights

Live Market Insights

ARS Pharmaceuticals Says CHMP Of European Medicines Agency Adopted Positive Opinion On Application For Marketing Authorization For EURneffy (Adrenaline Nasal Spray)

ARS Pharmaceuticals Q1 2024 GAAP EPS $(0.11), Inline

ARS Pharmaceuticals Submits Response For neffy Marketing Authorization Application To EMA's CHMP And Enters License Agreement With CSL Seqirus For Commercialization Of neffy In Australia And New Zealand

$SPRY
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by ARS Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by ARS Pharmaceuticals Inc.

SEC Form SC 13D/A filed by ARS Pharmaceuticals Inc. (Amendment)

$SPRY
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF MEDICAL OFFICER Tanimoto Sarina sold $1,394,960 worth of shares (100,000 units at $13.95) (SEC Form 4)

PRESIDENT AND CEO Lowenthal Richard E sold $1,394,960 worth of shares (100,000 units at $13.95) (SEC Form 4)

PRESIDENT AND CEO Lowenthal Richard E sold $1,684,642 worth of shares (100,000 units at $16.85) (SEC Form 4)

ARS Pharmaceuticals Says CHMP Of European Medicines Agency Adopted Positive Opinion On Application For Marketing Authorization For EURneffy (Adrenaline Nasal Spray)

Chat with this insight

Recent Analyst Ratings for $SPRY

$SPRY Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Ra Capital Management, L.P. bought $13,289,410 worth of shares (1,401,299 units at $9.48) (SEC Form 4)

$SPRY SEC Filings

SEC Form 10-Q filed by ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 8-K filed by ARS Pharmaceuticals Inc.

$SPRY Press Releases

Fastest customizable press release news feed in the world

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

$SPRY Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on ARS Pharmaceuticals

ARS Pharmaceuticals upgraded by Raymond James with a new price target

Leerink Partners reiterated coverage on ARS Pharmaceuticals with a new price target

$SPRY Financials

Live finance-specific insights

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

$SPRY Market Insights

Live Market Insights

ARS Pharmaceuticals Says CHMP Of European Medicines Agency Adopted Positive Opinion On Application For Marketing Authorization For EURneffy (Adrenaline Nasal Spray)

ARS Pharmaceuticals Q1 2024 GAAP EPS $(0.11), Inline

ARS Pharmaceuticals Submits Response For neffy Marketing Authorization Application To EMA's CHMP And Enters License Agreement With CSL Seqirus For Commercialization Of neffy In Australia And New Zealand

$SPRY Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by ARS Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by ARS Pharmaceuticals Inc.

SEC Form SC 13D/A filed by ARS Pharmaceuticals Inc. (Amendment)

$SPRY Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF MEDICAL OFFICER Tanimoto Sarina sold $1,394,960 worth of shares (100,000 units at $13.95) (SEC Form 4)

PRESIDENT AND CEO Lowenthal Richard E sold $1,394,960 worth of shares (100,000 units at $13.95) (SEC Form 4)

PRESIDENT AND CEO Lowenthal Richard E sold $1,684,642 worth of shares (100,000 units at $16.85) (SEC Form 4)

Recent Analyst Ratings for
$SPRY

$SPRY
Insider Purchases

$SPRY
SEC Filings

$SPRY
Press Releases

$SPRY
Analyst Ratings

$SPRY
Financials

$SPRY
Market Insights

$SPRY
Large Ownership Changes

$SPRY
Insider Trading